Choice of oral Presentations
Josep Tabernero, Eric Van Cutsem, Yung-Jue Bang, Charles S. Fuchs, et al.
Hedy L. Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, et al.
Margaret A. Tempero, Michele Reni, Hanno Riess, Uwe Pelzer, et al.
Conclusions: IR DFS with nab-P/G was not significantly longer vs G; median DFS with G was longer than historical data. DFS by investigator (sensitivity analysis) and interim OS were improved with nab-P/G vs G (HR 0.82 for both). Adjuvant nab-P/G may be an option for pts who are ineligible for FOLFIRINOX. Additional OS follow-up may better support nab-P/G as an option in the adjuvant setting. Clinical trial information: NCT01964430
Namiki Izumi, Kiyoshi Hasegawa, Yujiro Nishioka, Tadatoshi Takayama, et al.
Conclusions: SUR and RFA were both safe therapeutic approaches and provided equally RFS for early stage HCC smaller than 3 cm. Clinical trial information: UMIN000001795.